Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 318

1.

Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.

Paton DM.

Drugs Today (Barc). 2019 Dec;55(12):727-734. doi: 10.1358/dot.2019.55.12.3078389.

PMID:
31942875
2.

Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.

Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, Dobbyn A, Guerraty MA, Judy R, Kay J, Kember RL, Levin MG, Saha A, Van Vleck T, Verma SS, Weaver J, Abul-Husn NS, Baras A, Chirinos JA, Drachman B, Kenny EE, Loos RJF, Narula J, Overton J, Reid J, Ritchie M, Sirugo G, Nadkarni G, Rader DJ, Do R.

JAMA. 2019 Dec 10;322(22):2191-2202. doi: 10.1001/jama.2019.17935.

PMID:
31821430
3.

Transthyretin Amyloid Neuropathy: The Schwann Cell Hypothesis.

Murakami T, Sunada Y.

Adv Exp Med Biol. 2019;1190:371-378. doi: 10.1007/978-981-32-9636-7_24. Review.

PMID:
31760657
4.

Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.

De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Frusconi S, Manfellotto D, Fuciarelli M, Polimanti R.

Hum Genet. 2019 Dec;138(11-12):1331-1340. doi: 10.1007/s00439-019-02078-6. Epub 2019 Oct 29.

PMID:
31659433
5.

Characteristics of acquired transthyretin amyloidosis: A case series and review of the literature.

Misumi Y, Ueda M, Masuda T, Tsuda Y, Nomura T, Okada M, Inoue Y, Tasaki M, Obayashi K, Yamashita T, Ando Y.

Neurology. 2019 Oct 22;93(17):e1587-e1596. doi: 10.1212/WNL.0000000000008360. Epub 2019 Sep 11. Review.

PMID:
31511348
6.

Author response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.

Inês M, Coelho T, Costa J.

Neurology. 2019 Jul 30;93(5):229. doi: 10.1212/WNL.0000000000007876. No abstract available.

PMID:
31358675
7.

Reader response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.

Ueda M, Yamashita T, Misumi Y, Masuda T, Ando Y.

Neurology. 2019 Jul 30;93(5):228-229. doi: 10.1212/WNL.0000000000007870. No abstract available.

PMID:
31358673
8.

Noninvasive diagnosis of hereditary transthyretin-related cardiac amyloidosis: A case report.

Qin J, Zhan C, Li H, Han Y, Wang H, Li R, Ma F, Yan J.

Medicine (Baltimore). 2019 Jul;98(30):e16566. doi: 10.1097/MD.0000000000016566.

9.

The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan.

Sekijima Y, Mundayat R, Ishii T, Ando Y.

Amyloid. 2019;26(sup1):61-62. doi: 10.1080/13506129.2019.1583182. No abstract available.

PMID:
31343365
10.

A case report of osteoarthritis associated with hereditary transthyretin amyloidosis ATTRV30M.

Anan I, Bång J, Lundgren HE, Wixner J, Westermark P.

Amyloid. 2019;26(sup1):29-30. doi: 10.1080/13506129.2019.1593132. No abstract available.

PMID:
31343355
11.

The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.

Wixner J, Westermark P, Ihse E, Pilebro B, Lundgren HE, Anan I.

Amyloid. 2019;26(sup1):39-40. doi: 10.1080/13506129.2019.1593133. No abstract available.

PMID:
31343354
12.

Common clinicopathological features in late-onset hereditary transthyretin amyloidosis (Ala97Gly, Val94Gly and Val30Met).

Koike H, Nakamura T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Yasuda T, Mukai E, Date Y, Shiomi K, Nakazato M, Katsuno M, Sobue G.

Amyloid. 2019;26(sup1):24-25. doi: 10.1080/13506129.2019.1582495. No abstract available.

PMID:
31343348
13.

Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study.

Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G.

Amyloid. 2019;26(sup1):26. doi: 10.1080/13506129.2019.1582496. No abstract available.

PMID:
31343346
14.

Cardiovascular autonomic functions in late-onset hereditary transthyretin amyloidosis with Val30Met mutation.

Nakamura T, Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G.

Amyloid. 2019;26(sup1):6. doi: 10.1080/13506129.2019.1582018. No abstract available.

PMID:
31343341
15.

Changes in nerve excitability indices in hereditary transthyretin amyloidosis.

Yamashita T, Ueda M, Misawa S, Inoue Y, Masuda T, Misumi Y, Takamatsu K, Obayashi K, Kuwabara S, Ando Y.

Amyloid. 2019;26(sup1):9-10. doi: 10.1080/13506129.2019.1582480. No abstract available.

PMID:
31343340
16.

Cardiac involvement in a large cohort of patients with Val30Met transthyretin amyloidosis from Majorca focus.

Ripoll-Vera T, Alvarez J, Buades J, Cisneros E, Gomez Y, Melia C, Ferrer A, Losada I, Gonzalez J, Uson M, Figuerola A.

Amyloid. 2019;26(sup1):15-16. doi: 10.1080/13506129.2019.1582482. No abstract available.

PMID:
31343338
17.

Cardiac involvement after liver transplantation in patients with Val30Met transthyretin amyloidosis from Majorca focus.

Ripoll-Vera T, Alvarez J, Buades J, Cisneros E, Gomez Y, Melia C, Ferrer A, Losada I, Gonzalez J, Uson M, Figuerola A.

Amyloid. 2019;26(sup1):18-19. doi: 10.1080/13506129.2019.1582487. No abstract available.

PMID:
31343328
18.

Amyloidotic breast nodule in hereditary transthyretin amyloidosis (hATTR): a case report.

Cisneros-Barroso E, Losada-López I, González-Moreno J, Buades J, Ferrer-Nadal A, Ripoll-Vera T, Usón M, Figuerola A, Montalà JC, Descals C, Salva-Ramonell F, Torres-Rovira J, Gene-Heym A, Fernández-Burgos I, Soler T.

Amyloid. 2019;26(sup1):59-60. doi: 10.1080/13506129.2019.1582521. No abstract available.

PMID:
31343326
19.

Downregulated Cathepsin E expression in bone marrow-derived macrophages from the pre-clinical familial amyloid polyneuropathy model.

Moreira J, Saraiva M, Saraiva MJ.

Amyloid. 2019;26(sup1):63-64. doi: 10.1080/13506129.2019.1585342. No abstract available.

PMID:
31343320
20.

Self-reported gastrointestinal symptoms are more common in liver transplanted transthyretin amyloidosis patients than in healthy controls and in patients transplanted for end-stage liver disease.

Marberg T, Karling P, Söderberg K, Anan I, Wixner J.

Amyloid. 2019;26(sup1):47-48. doi: 10.1080/13506129.2019.1582514. No abstract available.

PMID:
31343318

Supplemental Content

Loading ...
Support Center